Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS by Smith, Bradley N et al.
 
 
University of Birmingham
Exome-wide rare variant analysis identifies TUBA4A
mutations associated with familial ALS
Smith, Bradley N; Morrison, Karen; Pall, Hardev; Ticozzi, Nicola; Fallini, Claudia; Gkazi,
Athina Soragia; Topp, Simon; Kenna, Kevin P; Scotter, Emma L; Kost, Jason; Keagle,
Pamela; Miller, Jack W; Calini, Daniela; Vance, Caroline; Danielson, Eric W; Troakes, Claire;
Tiloca, Cinzia; Al-Sarraj, Safa; Lewis, Elizabeth A; King, Andrew
DOI:
10.1016/j.neuron.2014.09.027
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Smith, BN, Morrison, K, Pall, H, Ticozzi, N, Fallini, C, Gkazi, AS, Topp, S, Kenna, KP, Scotter, EL, Kost, J,
Keagle, P, Miller, JW, Calini, D, Vance, C, Danielson, EW, Troakes, C, Tiloca, C, Al-Sarraj, S, Lewis, EA, King,
A, Colombrita, C, Pensato, V, Castellotti, B, de Belleroche, J, Baas, F, ten Asbroek, ALMA, Sapp, PC, McKenna-
Yasek, D, McLaughlin, RL, Polak, M, Asress, S, Esteban-Pérez, J, Muñoz-Blanco, JL, Simpson, M, van
Rheenen, W, Diekstra, FP, Lauria, G, Duga, S, Corti, S, Cereda, C, Corrado, L, Sorarù, G, Williams, KL,
Nicholson, GA, Blair, IP, Dion, PA, Leblond, CS, Rouleau, GA, Hardiman, O, Veldink, JH & SLAGEN Consortium
2014, 'Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS', Neuron, vol.
84, no. 2, pp. 324-31. https://doi.org/10.1016/j.neuron.2014.09.027
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
NOTICE: this is the author’s version of a work that was accepted for publication in Neuron. Changes resulting from the publishing process,
such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document.
Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in
Neuron, VOL 84, ISSUE 2, 22 October 2014 DOI:10.1016/j.neuron.2014.09.027
Eligibility for repository checked February 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
 1 
Exome-Wide Rare Variant Analysis Identifies  
TUBA4A Mutations Associated with Familial ALS 
  
Bradley N. Smith1,30, Nicola Ticozzi2,3,30, Claudia Fallini4,30, Athina Soragia Gkazi1,30, 
Simon Topp1,30, Kevin P. Kenna4,5, Emma L. Scotter1, Jason Kost4,6, Pamela Keagle4, 
Jack W. Miller1, Daniela Calini2,3, Caroline Vance1, Eric W. Danielson4, Claire Troakes1, 
Cinzia Tiloca2, Safa Al-Sarraj1, Elizabeth A. Lewis4, Andrew King1, Claudia 
Colombrita2,3, Viviana Pensato7, Barbara Castellotti7, Jacqueline de Belleroche8, Frank 
Baas8, Anneloor LMA ten Asbroek9, Peter C. Sapp4, Diane McKenna-Yasek4, Russell L. 
McLaughlin5, Meraida Polak10, Seneshaw Asress10, Jesús Esteban-Pérez11, José Luis 
Muñoz-Blanco12, Michael Simpson13, SLAGEN Consortium, Wouter van Rheenen14, 
Frank P. Diekstra14, Giuseppe Lauria15, Stefano Duga16, Stefania Corti3,17, Cristina 
Cereda18, Lucia Corrado19, Gianni Sorarù20, Karen E. Morrison21,22, Kelly L. Williams23, 
Garth A. Nicholson23,24, Ian P. Blair23, Claire S. Leblond25, Guy A. Rouleau25, Orla 
Hardiman5, Jan H. Veldink14, Leonard H. van den Berg14, Ammar Al-Chalabi26, Hardev 
Pall27, Pamela J. Shaw28, Martin R. Turner29, Kevin Talbot29, Franco Taroni7, Alberto 
García-Redondo11, Zheyang Wu6, Jonathan D. Glass10, Cinzia Gellera7, Antonia Ratti2,3, 
Robert H. Brown Jr.4, Vincenzo Silani2,3,31, Christopher E. Shaw1,31, John E. 
Landers4,30,31,* 
 
1Centre for Neurodegeneration Research, King’s College London, Department of Clinical Neuroscience, 
Institute of Psychiatry, London SE5 8AF, UK. 
2Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan 
20149, Italy. 
3Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center - Università degli Studi di 
Milano, Milan 20122 Italy. 
4Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 
01605, USA. 
5Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, 
Republic of Ireland. 
6Worcester Polytechnic Institute, Worcester, MA 01609, USA. 
7Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico 
‘Carlo Besta’, Milan 20133, Italy. 
8Neurogenetics Group, Division of Brain Sciences, Hammersmith Hospital Campus, Burlington Danes 
Building, Du Cane Road, London W12 0NN. 
9Department of Genome analysis and Neurogenetics, Academic Medical Centre, Amsterdam, The 
Netherlands. 
10Department of Neurology, Emory University, Atlanta, GA 30322, USA. 
11Unidad de ELA, Instituto de Investigación Hospital 12 de Octubre de Madrid, SERMAS, and Centro de 
Investigación Biomédica en Red de Enfermedades Raras (CIBERER U-723), Madrid, Spain. 
12Unidad de ELA, Instituto de Investigación Hospital Gregorio Marañón de Madrid, SERMAS, Spain. 
13Department of Genetics and Molecular Medicine, King’s College London. Tower Wing, Guy’s Hospital, 
London SE1 7EH, UK. 
Manuscript
 2 
14Department of Neurology, Brain Center Rudolf Magnus Institute of Neuroscience, University Medical 
Centre Utrecht, 3508 GA Utrecht, The Netherlands. 
15Headache and Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, Milan 20133, 
Italy. 
16Department of Medical Biotechnology and Translational Medicine - Università degli Studi di Milano, 
Milan, Italy. 
17Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy. 
18Experimental Neurobiology Laboratory, IRCCS 'C. Mondino' National Neurological Institute, 27100 
Pavia, Italy. 
19Department of Medical Sciences, 'A. Avogadro' University of Eastern Piedmont, Novara, Italy. 
20Department of Neurosciences, University of Padova, Padova, Italy. 
21School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of 
Birmingham, UK. 
22Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust UK. 
23Australian School of Advanced Medicine, Macquarie University, Sydney, NSW 2109, Australia. 
24Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139, Australia. 
25Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, 
Montreal, Quebec, Canada. 
26Department of Clinical Neuroscience, Medical Research Council Centre for Neurodegeneration 
Research, Institute of Psychiatry, King’s College London, London, UK. 
27School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, The University 
of Birmingham, Birmingham, UK. 
28Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK. 
29Nuffield Department of Clinical Neurosciences, University of Oxford, UK. 
30,31These authors contributed equally to this work. 
* Correspondence:  john.landers@umassmed.edu. 
 
 
RUNNING TITLE: Identification of TUBA4A Mutations in ALS 
 
SUMMARY 
Exome sequencing has proven to be an effective strategy for identifying human disease 
genes. However, this methodology can be difficult in late-onset diseases where limited 
availability of DNA from informative family members often prohibits comprehensive 
segregation analysis. To overcome this limitation, we performed a exome-wide rare 
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variant burden analysis of 363 index cases with familial ALS (FALS). The results 
revealed an excess of patient variants within TUBA4A, the gene encoding the Tubulin, 
Alpha 4A protein. Analysis of a further 272 FALS cases and 5510 internal controls 
confirmed the over representation as both statistically significant and replicable. 
Functional analyses revealed that TUBA4A mutants lead to a destabilized microtubule 
network and diminished repolymerization capability. Taken together, these results 
further emphasize the role of cytoskeletal defects in ALS. Moreover, they demonstrate 
the power of gene based rare variant analyses in situations where causal genes cannot 
be identified through traditional segregation analysis.  
 
HIGHLIGHTS 
 Mutations in tubulin, alpha 4A (TUBA4A) are associated with familial ALS 
 TUBA4A mutants act as dominant negatives to alter microtubule dynamics and stability  
 Further evidence supports a major role of cytoskeletal defects in ALS pathogenesis 
 Rare variant analysis of index familial cases can identify human disease genes  
 
INTRODUCTION 
The identification of mutations for human disorders is critical for our understanding of 
their pathogenesis. Over the past few years, numerous studies have successfully used 
exome sequencing to rapidly identify novel disease genes. Despite these advances, this 
approach is still limited by the fact that each individual harbors hundreds of rare 
variants, thus requiring DNA from multiple affected individuals from an affected family 
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for this method to be successful. Unfortunately, for many diseases the DNA collection of 
multiple affected samples from the same family can be difficult. This is especially true 
for familial amyotrophic lateral sclerosis (FALS), a late-onset, rapidly progressive 
neurodegenerative disease. As such, there is a need to develop approaches to use 
individual affected cases to identify disease genes. Exome-wide rare variant analysis 
has been proposed as a promising alternative strategy for disease gene identification 
(Panoutsopoulou et al., 2013; Stitziel et al., 2011). By this approach, the total number of 
gene variants seen among cases is compared to that seen among controls. Threshold 
minor allele frequency and possibly functional significance filters are implemented to 
prevent statistical noise from common or other neutral variants masking true gene 
associations. Importantly, although an abundance of variants in cases suggests the 
presence of pathogenic mutations, an associated variant set will still likely include 
neutral variants in both cases and controls. Given that these methods do not rely on 
related samples, we decided to use this approach to identify novel causative genes for 
familial ALS. 
 
RESULTS 
We performed exome sequencing on a discovery cohort of 363 index cases (i.e. one 
affected sample per family) collected from 6 countries (Ireland, Italy, Netherlands, 
Spain, UK, US) (see Table S1 available online) devoid of causative mutations/ repeat 
expansions in known ALS genes (SOD1, C9orf72, TARDBP, FUS, PFN1, UBQLN2, 
OPTN, VCP, ANG). An average of 3.2 x 109 target bases were sequenced per sample 
to an average depth of 90.4X (Tables S2 and S3). Control exome data included 4300 
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European Americans available through the NHLBI’s Exome Variant Server 
(EVS)(Tennessen et al., 2012), and 31 internally sequenced samples. As proof of 
principle, we spiked our sample set with 9 FALS exomes from individuals with known 
causative mutations (6 in SOD1 and 3 in VCP). The analysis was restricted to the 
12,487 genes fulfilling all quality control filters and to variants either predicted to be 
damaging using PolyPhen-2 or resulting in a stop gain/loss. Variants were also only 
considered if they exhibited minor allele frequencies less than 0.04% in keeping with 
previously reported ALS mutations (Chio et al., 2012; Kenna et al., 2013) (Supplemental 
Experimental Procedures) and the significance of disease associations following 
multiple test correction (Pcorrected) were calculated using permutation procedures (Kiezun 
et al., 2012). Strong signals of disease association were observed across SOD1 (6 
cases [1.6%] vs 0 controls, P=5.5 x 10-8, Pcorrected=6.2 x 10-4) and VCP (3 cases [0.8%] 
vs 0 controls, P=1.1 x 10-4, Pcorrected=0.73) (Figure 1A and Figure S1). Excluding SOD1, 
the top hit from our analysis was TUBA4A, encoding the Tubulin, Alpha 4A protein (4 
cases [1.1%] vs 0 controls, P=9.1 x 10-6, Pcorrected=0.09). The gene is well covered by 
EVS confirming that the P-value was not inflated due to poor control sequencing (Figure 
S2). TUBA4A also exhibited associations of similar significance when alternative 
bioinformatic tools were used to identify putatively damaging disease variants (SIFT, 
GERP, MutationTaster, phyloP). Furthermore, TUBA4A ranked 1st or 2nd in all tests 
(Table S4 and Figure S3) while no other gene ranked in the top 10 hits for all 5 tests. 
Although TUBA4A was the most consistent hit, our strategy revealed several other 
strong candidate genes for FALS (Figure 1A, Table S4, Supplemental Files) including 
MATR3, responsible for distal myopathy 2 and recently identified by another group as 
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causative for FALS (Johnson et al., 2014). Other candidate genes include STK24, a 
mediator of oxidative-stress-induced cell death, and LRRFIP1, a GC-rich DNA/double 
stranded RNA binding protein (UniProtKB). Based on these results, we further 
investigated TUBA4A as a candidate gene associated with FALS. 
 
Exome sequencing revealed a total of 5 non-synonymous TUBA4A changes, all of 
which localized to exon 4 and confirmed by Sanger sequencing (Table S5 and Figure 
S4). None of these mutations were observed in the 4300 European American EVS 
controls and all occurred within highly conserved positions (Figure 1B). The mutations 
included 2 missense changes in the same residue (R320C/H) and a nonsense mutation 
(W407X) removing the last 41 amino acids. This C-terminal region contacts the tubulin 
beta subunit as well as the motor domain of kinesins and other microtubule-associated 
proteins (Howes et al., 2014; Liu et al., 2012) (Figure 1C). Additional missense changes 
included a R215C and A383T mutation. PolyPhen-2 predicted 4 of the 5 mutations to be 
deleterious (Table S6). In contrast, only three non-synonymous changes were observed 
in the 4300 EVS controls and none were predicted to be damaging. No relatives of the 
affected patients were available to test segregation.  
 
To further evaluate TUBA4A as a causative ALS gene, an independent replication 
cohort comprising a further 272 index FALS cases and 5510 internal European 
American controls was sequenced for rare damaging exon 4 variants (Table S7). 
Reimplementation of the variant filtering strategies employed during the discovery 
analysis and subsequent testing using Fisher’s exact method again revealed a 
significant excess of mutation carriers among patients (2 cases [0.65%] vs 2 controls 
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[0.04%], P=1.5x10-2). A combined analysis of the discovery and replication cohorts 
resulted in a statistically significant over abundance of rare variants after multiple test 
correction (OR=36 [95% CI:10-210], P=4.3x10-7, Pcorrected=4.2x10-3). Mutation carriers 
observed among patients from the replication cohort included a single carrier of a 
T145P variant and a single carrier of a K430N variant. Screening of an affected parent 
and unaffected sibling confirmed the expected segregation pattern in the case of T145P 
(Figure S5). The K430N variant was not detected in an affected first cousin of the 
sequenced proband (Figure S5) suggesting that this is either a neutral polymorphism, 
as is often observed in rare variant analyses, or the two affected family members 
represent phenocopies. Variants identified in the control cohort included E386K and 
G365E substitutions but no variant detected in FALS patients from either the discovery 
or replication cohorts. Sequencing of the entire coding region in 1355 sporadic ALS 
cases also identified a G43V mutation in a single sample (Table S5). This variant was 
predicted to be benign by PolyPhen-2 and detected within 1 control from the internal 
replication panel. No TUBA4A mutations were identified in 131 ALS samples (89 FALS 
and 42 SALS) with known causative mutations/repeat expansions (Table S8). 
 
All patients carrying TUBA4A mutations had spinal-onset, classical ALS, with upper and 
lower motor neuron signs. Two cases developed during the course of the disease a 
cognitive decline of frontal type, consistent with a diagnosis of frontotemporal dementia 
(FTD) and another had a first-degree relative with FTD (Figure S5 and Table S9). 
Screening of samples analyzed by the 1000Genome project (1053 samples) and 2200 
African Americans from the EVS revealed the A383T mutation within a single individual 
of African ancestry. Therefore, with the exception of A383T and G43V, the set of 
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observed patient variants were not detected within a total of 13,023 control samples  
(Table S10).  
 
TUBA4A Mutants Display Altered Incorporation Into Microtubules 
Since several causative ALS proteins have been shown to form insoluble inclusions in 
postmortem brain tissues and in cell culture, we investigated the ability of TUBA4A 
mutants identified in our initial analysis to aggregate by expressing HA-tagged TUBA4A 
constructs in primary motor neurons (PMNs) and HEK293 cells. Interestingly, the 
W407X mutant did not incorporate into the microtubule network and formed small 
ubiquitinated cytoplasmic inclusions in ~40% of transfected PMNs and ~85% of 
transfected HEK293 cells (Figure 2A,B; Figure S6 and S7). Immunohistochemistry of 
brain and spinal cord tissue from sporadic ALS cases (without mutations) yielded a 
clear staining of the perikarya and neuropil region in both the spinal cord and motor 
cortex, however no TUBA4A aggregates were identified (Figure S8). No coaggregation 
was observed in cells co-expressing an aggregation-prone TDP-43 C-terminal fragment 
and wild-type TUBA4A (Figure S9). While the other TUBA4A mutants formed 
cytoplasmic inclusions in 10-30% of transfected HEK293 cells (data not shown), no 
aggregation was observed in PMNs. However, subtle alterations in their cytoplasmic 
distribution were observed, such as a more diffuse cytoplasmic staining compared to 
the wild-type protein, which was mainly incorporated into the microtubule network 
(Figure 2A). We thus investigated the ability of mutant TUBA4A to efficiently form 
microtubules using a cell-free system to quantify the incorporation of the mutant 
TUBA4A into alpha/beta tubulin dimers (Cleveland et al., 1978; Jaglin et al., 2009; Tian 
 9 
et al., 2010). Each mutant was subjected to in vitro translation in rabbit reticulocyte 
lysate that contains all components needed to form tubulin dimers. The products were 
then analyzed by non-denaturing gel electrophoresis to measure incorporation of the 
translated recombinant protein into tubulin dimers. SDS-gel electrophoresis was 
performed in parallel to control for equal protein synthesis and loading. Interestingly, the 
TUBA4AW407X protein yielded no discernible dimers, while the A383T and both R320 
mutants displayed significantly lower levels of assembly relative to the wild-type protein 
(Figure 2C,D). The other mutants did not differ from the control, save for a small but 
reproducible migration difference for TUBA4AR215C protein. In parallel, we then tested 
the incorporation of mutant TUBA4A into microtubules in cultured cells. We chose 
primary astroglial cells for the HA-tagged TUBA4A transfections, as they have a large 
cytoplasm and a relatively long cell cycle that result in an extensive and stable 
microtubule network. We performed an unbiased analysis of the cytoskeletal 
incorporation of HA-tagged TUBA4A constructs by applying a circularity filter to the 
images in order to discriminate between filamentous and diffuse granular staining 
(Supplemental Experimental Procedures). The ratio between the fluorescence 
intensities of the filamentous versus overall staining, ranging from 1 to 0, was used to 
categorize each cell as normal (1-0.75), mild (0.75-0.5), moderate (0.5-0.25), or severe 
(0.25-0) phenotype (Figure 2E,F and Figure S10). The wild-type HA-tagged TUBA4A 
protein yielded nearly 70% of cells displaying a high level of microtubule incorporation 
(Figure 2E,F). In contrast, several of the mutants displayed an altered incorporation into 
microtubules. In particular, the W407X yielded the most dramatic effect with an absence 
of tagged protein in the microtubule network and the presence of multiple aggregate-like 
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inclusions. The R320C/H, A383T and R215C mutants all displayed a significantly 
different distribution relative to the wild-type, but no differences were detected for the 
G43V protein.  
 
TUBA4A Mutants Disrupt Microtubule Dynamics and Stability Through a Dominant-
Negative Mechanism 
We next determined whether TUBA4A mutants affected microtubule assembly 
dynamics by testing the ability of TUBA4A-transfected COS7 cells to recover after 
transient microtubule depolymerization following treatment with 10 µM nocodazole 
(Figure 3)(Gilissen et al., 2011; Tian et al., 2007; 2010). For this assay, the wild-type, 
R320C, and W407X proteins were compared, as these mutants displayed an 
intermediate and severe phenotype respectively in the previous experiments. While 
~80% of cells transfected with TUBA4AWT formed centrosomes positive for the HA-
tagged TUBA4A protein within 5 minutes of nocodazole removal, only ~20% of 
TUBA4AR320C-transfected cells formed a new microtubule network containing the mutant 
protein at 15 minutes. Interestingly, the expression of mutant TUBA4A also impaired the 
ability of the endogenous protein to form microtubules, as only 50% of the cells 
contained TUBA4A-positive microtubules after 15 minutes, compared to ~90% in wild-
type transfected cells (Figure 3A,B and Figure S11). Similar results were also observed 
in cells containing TUBA4AW407X–positive aggregates. On the contrary, cells expressing 
the TUBA4AW407X mutant without the presence of aggregates did not display any defect 
in the rate of microtubule repolymerization (Figure 3C,D). These results suggest that 
mutant TUBA4A by incorporating into the microtubules may disrupt their dynamics 
through a dominant-negative mechanism. 
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To pursue this hypothesis further, we investigated whether TUBA4A mutants would 
influence the overall stability of the microtubule network. Primary motor neurons were 
transfected with wild-type and mutant TUBA4A constructs, permeabilized with 0.1% 
Triton X-100 to extract all soluble proteins before fixation and immunostained for HA-
TUBA4A and β-tubulin. Under these conditions, the microtubule cytoskeleton was 
largely preserved in wild-type transfected neurons, whereas each of the missense 
mutants resulted in decreased HA-TUBA4A and β-tubulin immunofluorescence (Figure 
4A-C). The TUBA4AW407X mutant yielded no cells with visible HA staining (data not 
shown) indicating a complete failure of incorporation into the network. Furthermore, the 
levels of α-tubulin acetylation, which have been shown to correlate with increased 
microtubule stability (Matsuyama et al., 2002; Piperno et al., 1987; Wu et al., 2012), 
were significantly reduced in mutant TUBA4A-expressing motor neurons (Figure 4D,E 
and Figure S12). Interestingly, the G43V mutation, which is uniquely localized to the 
protein N-terminus, did not impair tubulin acetylation, suggesting that defective binding 
of the acetyl-transferase αTAT1 to α-tubulin C-terminal tail (Howes et al., 2014; 
Panoutsopoulou et al., 2013; Stitziel et al., 2011), where TUBA4A mutations are 
clustered, may be responsible for this effect. Together, these results further suggest that 
missense mutants of TUBA4A weaken the microtubule network by a dominant-negative 
mechanism.  
 
DISCUSSION 
To summarize, we have used an unbiased case-control exome sequencing study to 
identify a statistically significant and replicable excess of rare damaging TUBA4A 
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variants in FALS. Disease-associated variants affect strongly conserved residues and in 
most cases are absent in over 13,000 controls. The positive identification of samples 
with mutations in the SOD1 and VCP genes, as well as in the newly discovered ALS 
gene MATR3 within the initial cohort, further proves the validity of our approach. Though 
our approach demonstrates the importance of a specific class of TUBA4A variant, an 
important limitation of the burden approach, which compares the number of rare 
variants in cases versus controls, is that it is not informative as to the effects of 
individual variants. It may therefore prove that not all reported patient mutations are 
pathogenically relevant or act with equal penetrance. An example of this is the identified 
K430N alteration that did not segregate in an affected first cousin suggesting that this is 
either a neutral variant or the two patients are phenocopies. However, our results from 
biological characterization provided strong evidence to support a deleterious effect of 
most variants. Specifically it was demonstrated that FALS associated variants 1) 
inefficiently form alpha/beta tubulin dimers in vitro; 2) display decreased incorporation 
into microtubules in cultured cells and 3) inhibit microtubule network assembly and 
reduce structural stability. Based on our functional data, TUBA4A mutants appear to 
disrupt microtubule dynamics and stability through a dominant-negative mechanism. 
Interestingly, the truncation mutant protein TUBA4AW407X is deficient in forming dimers 
or incorporating into the microtubule network suggesting that it may have a decreased 
ability to act as a dominant negative. This is illustrated by our observation that in cells 
expressing the W407X mutant without aggregates, there is no obvious defect in the rate 
of microtubule polymerization after nocodazole treatment. However, since TUBA4AW407X 
shows aggregation propensities analogous to other mutant proteins implicated in ALS 
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and other neurodegenerative diseases, its deleterious effect may be through a different 
mechanism, such as trapping tubulin-binding proteins into the aggregates or by over-
burdening the ubiquitin proteasome system. Additionally, the mutant protein 
TUBA4AG43V, found in a sporadic ALS case and in a control individual, did not display 
significant differences from the wild-type protein in its integration into microtubules nor 
in its influence on acetylation. These results suggest that this mutation may be a neutral 
variant or display lower penetrance. 
 
Mutations in at least 7 other tubulin family members (TUBA1A (Keays et al., 2007; 
Kumar et al., 2010; Poirier et al., 2007), TUBA8 (Abdollahi et al., 2009), TUBB2B (Jaglin 
et al., 2009), TUBB3 (Poirier et al., 2010; Tischfield et al., 2010), TUBB5 (Breuss et al., 
2012), TUBB4A (Hersheson et al., 2012; Tian et al., 2007), TUBG1 (Poirier et al., 
2013)) have been previously described to cause several neurodevelopmental and 
neurodegenerative disorders, suggesting that mutations in different tubulin subunits 
may have specific effects within the central nervous system. For instance, mutations in 
the β-tubulin gene TUBB3 have been shown to disrupt KIF-mediated axonal transport, 
resulting in widespread axon loss both in the CNS and in the peripheral nervous system 
(Niwa et al., 2013) while mutations in TUBA1A impairs neuronal migration, thus causing 
severe brain dysgenesis. Moreover, the progressive motor neuronopathy (pmn) mutant 
mouse, a commonly used model for human motor neuron disease, is the result of a 
mutation in the Tubulin-specific Chaperone E (TBCE) gene (Bömmel et al., 2002; Martin 
et al., 2002). Most mutant tubulin protein show similar functional defects compared to 
TUBA4A mutants, such as impaired dimerization and microtubule incorporation, and yet 
cause very different phenotypes. Interestingly, results from the BrainSpan Atlas show 
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that in the primary motor cortex, most α- and β-tubulin subunits responsible for 
developmental defects are highly expressed early during brain development and 
decrease with age, whereas TUBA4A levels increase dramatically (>50-fold) with age 
(Figure S13). These results are recapitulated in microarray data of developing mouse 
brain tissue (E14-P14)(Figure S14)(Pramparo et al., 2011) which show a ~30-fold 
increase of TUBA4A. Furthermore, similar to TUBA4A, expression of TUBB4A also 
increases over time (Figure S13-S14) and mutations in this gene are responsible for a 
disease with a onset age of 15-37 years (torsion dystonia type 4)(Hersheson et al., 
2012). These observations may partially explain the difference between the 
neurodevelopmental and late onset symptoms associated to the different tubulin 
mutations. 
 
TUBA4A is ubiquitously expressed in human tissues with its highest expression in brain 
(ArrayExpress, Accession E-MTAB-513 [Illumina BodyMap])(Rustici et al., 2013). 
Although a downregulation of genes encoding for -tubulin subunits has been reported 
in spinal motor neurons of SALS patients (Jiang et al., 2005), no specific role has been 
described for TUBA4A in motor neurons so far. It must be noticed, however, that 
although the majority of known ALS-causing genes are ubiquitously expressed, very 
little is still known about their specific effects on motor neurons. TUBA4A joins other 
ALS-associated genes encoding for cytoskeletal proteins, such as PFN1 (Wu et al., 
2012), DCTN1 (Puls et al., 2003), PRPH (Gros-Louis, 2004), and NEFH (Al-Chalabi et 
al., 1999), thus strengthening the hypothesis that alterations affecting the cytoskeleton 
architecture and dynamics have a major role in ALS pathogenesis. 
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SUPPLEMENTAL INFORMATION 
Supplemental Information includes Supplemental Data (sixteen figures, and ten tables), 
Supplemental Experimental Procedures, Supplemental Text, Supplemental References 
and Supplemental Files (two Excel spreadsheets) and can be found with this article 
online. 
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FIGURE LEGENDS 
Figure 1. Rare variant analysis identifies TUBA4A mutations in FALS. (A) 
Manhattan plot displaying permutation-based corrected P values generated by a rare 
variant analysis of FALS are shown. The dotted line represents a Pcorrected=0.05. The 
points in yellow, red and black for TUBA4A denote the P-value for the discovery, 
replication and joint analyses respectively. (B) The evolutionary conservation of 
TUBA4A mutations are displayed. Mutated residues are shown in red. (C) The 
interactions of bovine TUBA1B and TUBB2B with the rat kinesin KIF5B  (Protein Data 
Bank accession 4ATX) are shown using the PyMOL Molecular Graphics System 
(v.1.5.0.5). All relevant residues are identical between bovine TUBA1B and human 
TUBA4A. Light blue: α-tubulin; green: β-tubulin; orange: kinesin; red: residues identified 
as mutants in this study or deleted in the W407X individual; spheres: residues involved 
in inter-protein interactions. As shown, the C-terminal region interacts with both the β -
tubulin subunit and the kinesin motor domain. 
 
Figure 2. Mutant TUBA4A alters microtubule polymerization. (A) Primary motor 
neurons transfected with HA-tagged TUBA4A constructs. (B) HEK293 cells transfected 
with wild-type or W407X mutant HA-TUBA4A constructs were immunostained for 
ubiquitin. Ubiquitin-positive aggregates were visible only in the HA-TUBA4AW407X-
transfected cells. (C) Non-denaturing (top) and SDS-gel electrophoresis (bottom) of HA-
 20 
TUBA4A constructs after in vitro translation. (D) The intensity of the bands representing 
the α/β tubulin dimers was quantified from 6 independent experiments. Bars represent 
mean and SEM (one-way ANOVA and Dunnett’s post hoc test, * p<0.05, *** p<0.001). 
(E) Primary astroglial cells were transfected with the HA-TUBA4A constructs and fixed 4 
days after transfection. The ratio between HA-TUBA4A protein distributions in filaments 
versus its overall levels was measured and divided into 4 categories from mainly 
filamentous to mainly diffuse. (F) The frequency of each phenotype was quantified and 
compared between the wild-type and mutant proteins (Kolmogorov-Smirnov test; n=75-
90 cells per condition from 3 independent experiments, ** p<0.01, *** p<0.001). From 
left to right, bars represent the relative frequency of the normal, mild, moderate, and 
severe phenotypes. Red, HA; green, ubiquitin; blue, DAPI. White boxes indicate the 
regions enlarged in the insets. Scale bars: 10µm.  
 
Figure 3. Mutant TUBA4A alters microtubule dynamics. (A, C) COS7 expressing 
wild-type and mutant TUBA4A were treated with 10µM nocodazole for 2 hours and 
allowed to recover in nocodazole-free medium for 2.5, 5, 10, or 15 minutes prior to 
fixation. Representative images are shown. Red, HA; green, TUBA4A; blue, DAPI. 
White boxes indicate the regions enlarged in the insets. Scale bars: 10µm. (B, D) The 
percentage of cells containing microtubules positive for the HA-tagged (red) or the 
endogenous TUBA4A protein (green) at different time points was quantified from more 
than 100 cells per condition from three independent experiments and compared 
between wild-type and mutant TUBA4A (one-way ANOVA and Dunnett’s post hoc test; 
 21 
n=3, * p<0.05, ** p<0.01, *** p<0.001). For the TUBA4AW407X mutant, cells were 
analyzed separately based on the presence of cytoplasmic inclusions. 
      
Figure 4. Mutant TUBA4A destabilizes the microtubule network. (A) PMNs 
transfected with wild-type or mutant TUBA4A constructs were permeabilzed with 0.1% 
Triton X-100 for 5 minutes prior to fixation. (B, C) The fluorescence intensity of HA-
TUBA4A (red) and β-tubulin (green) was quantified and compared. Bars represent 
mean and SEM (Kruskas-Wallis test, n=23-34 cells per condition from 3 independent 
experiments, * p<0.05, ** p<0.01, *** p<0.001). (D, E) Acetylated tubulin (green) levels 
were measured in motor neurons expressing TUBA4A mutants (red). Representative 
images are shown. Bars represent mean and SEM (one way ANOVA and Dunnett’s 
post hoc test, n=30-45 cells per condition from 3 independent experiments, * p<0.05, ** 
p<0.01). DAPI (blue) was used to identify the nucleus. Scale bars: 10µm.  
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INVENTORY OF SUPPLEMENTAL INFORMATION 
 
 
Figure S1. Manhattan plot of uncorrected P-values obtained by gene-based 
rare-variant analysis. Represents data shown in Figure 1A prior to multiple test 
correction. 
 
Figure S2. Sequencing quality of TUBA4A by the NHLBI’s Exome Variant 
Server. Provides addition support that the top hit in Figure 1A is not due to poor 
sequencing. 
 
Figure S3. QQ Plots of rare variant analysis for familial ALS. Demonstrates 
the results shown in Figure 1A do not display genomic inflation. 
 
Figure S4. Chromatograms of TUBA4A mutations. Provides sequence 
confirmation of the mutations identified in TUBA4A from the analysis in Figure 
1A. 
 
Figure S5. Familial ALS pedigrees with TUBA4A mutations. Provides the 
family structure of individuals harboring TUBA4A mutations identified from the 
analysis in Figure 1A and subsequent replication set. 
 
Figure S6. Protein fractionation of TUBA4A mutants. Provides confirmation of 
the aggregation observed in Figure 2B. 
 
Figure S7. Solubility of TUBA4A mutants. Provides confirmation of the 
aggregation observed in Figure 2B. 
 
Figure S8. TUBA4A staining of SALS cases and controls. Demonstrates a 
lack of aggregation, as opposed to the mutant W407X in Figure 2B, with wild-
type TUBA4A in sporadic ALS. 
 
Figure S9. Lack of co-localization of wild-type TUBA4A with TDP-43 
aggregates. Demonstrates a lack of aggregation, as opposed to the mutant 
W407X in Figure 2B, with wild-type TUBA4A and mutant TDP-43 co-expressed 
in cells. 
 
Figure S10. Quantitation of incorporation of TUBA4A in the microtubule 
network. Provides additional detail of the results presented in Figure 2E and F. 
 
Figure S11. Mutant R320C TUBA4A alters microtubule dynamics. Provides 
supporting results for Figure 3A and B. 
 
Figure S12. Altered microtubule acetylation in mutant TUBA4A expressing 
cells. Figures for additional mutants shown in Figure 4D.  
 
Inventory of Supplemental Information
Figure S13. Relative expression of tubulin subunits in the primary motor 
cortex with age. Provides support for material presented in the Discussion. 
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Figure S15. Relative expression of exogenous TUBA4A. Represents level of 
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Figure S16. Stratification analysis of exome sequenced samples. Provides 
analysis for the case samples used in Figure 1A. 
 
Table S1. Summary of samples subject to exome sequencing in the 
discovery cohort. Provides information on the cases used in Figure 1A. 
 
Table S2. Summary statistics for exome sequencing of the FALS discovery 
set. Provides information on the exome sequencing results used in Figure 1A. 
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Table S7. Summary of samples screened for TUBA4A mutations in the 
replication cohort. Country breakdown of the samples used in the replication set 
described in the main text. 
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Provides additional information on the samples with TUBA4A mutation identified 
from the discovery analysis and replication set (Figure 1B). 
 
Table S10. Analysis of TUBA4A mutations in control populations. Detailed 
information on TUBA4A mutation identified from the discovery analysis and 
replication set (Figure 1B). 
 
Supplemental Spreadsheet: BurdenTestResults.xls. Provides burden test 
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Supplemental Spreadsheet: TopGeneVariants.xls. Provides all variants in the 
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SUPPLEMENTAL DATA 
 
 
 
 
 
 
Figure S1. Manhattan plot of uncorrected P-values obtained by gene-based rare-
variant analysis. Gene-based rare variant analysis was perform using variants either 
predicted to be damaging using PolyPhen-2 or resulting in a stop gain/loss. Variants 
were also only considered if they exhibited minor allele frequencies in keeping with 
previously reported ALS mutations. The point in black represents the P-value of 
TUBA4A after the incorporation of data generated from the replication set. A Manhattan 
plot using corrected P-values is shown in Figure 1A. 
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Figure S2. Sequencing quality of TUBA4A by the NHLBI’s Exome Variant Server. 
The average read density of TUBA4A at each coding position by the ESP is plotted in 
blue. The number of samples that passed quality control measures, out of 4300 
samples, at each position is plotted in red.  
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Supplementary Figure 1 | Sequencing Quality of Tuba4a by the NHLBI Exome 
Sequencing Project (ESP).
Th  verag  rea  density o uba4a at each coding position by he ESP is plotted in blue. 
The number of samples that passed quality control measures at each position is plotted in 
red.
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Figure S3. QQ Plots of rare variant analysis for familial ALS. Variants identified 
through exome sequencing were filtered based on the method displayed. The remaining 
variants were subject to rare variant analysis. Expected P values are plotted against 
those obtained through our analysis. The black line represents results that would be 
obtained under the null hypothesis. The red triangle represents the P value resulting 
from spiked SOD1 mutant samples and the orange point represents the P value for 
TUBA4A. The genomic inflation factor is shown. 
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Figure S4. Chromatograms of TUBA4A mutations. Sequence traces of 
representative samples harboring either wild-type (left column) or mutant (right column) 
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Supplementary Figure 1 | Chromatograms of Tuba4a mutations. 
Sequence traces of representative samples harboring either wild-type (left column) or 
mutant (right column)
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Figure S5. Familial ALS pedigrees with TUBA4A mutations. Family structure for 
each mutation is shown. Black: ALS; grey: frontotemporal dementia; white: unaffected. 
The proband is indicated with an arrow. The asterisk indicates the genotype was 
inferred from the other family members. 
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Figure S6. Protein fractionation of TUBA4A mutants. (A) HEK cells were transfected 
with constructs expressing wild-type and mutant TUBA4A. Cellular lysates were subject 
to sequential extractions using the buffers indicated and immunblotted with anti-HA 
antibody. As shown, the majority of W407X mutant protein is insoluble in Triton X-100 
whereas the wild-type and missense mutants are soluble. (B) HA-TUBA4A levels were 
quantified in each fraction and represented as percentage of the total HA-TUBA4A 
protein. Bars represent mean and SEM (one-way ANOVA and Dunnett’s post hoc test, 
n=3, ** P<0.01). P, PBS; T, Triton X-100; S, SDS; U, urea. 
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Figure S7. Solubility of TUBA4A mutants. (A) HEK cells were transfected with 
constructs expressing wild-type and mutant TUBA4A. Total lysate (L), soluble (S) and 
insoluble (I) fractions were subject to Western blotting using antibodies directed against 
HA, Lamin and GAPDH. (B) Expression levels were quantified and the ratio of HA 
signal in the insoluble fraction to Lamin signal was calculated. Bars represent the mean 
and SEM (one way Kruskal-Wallis ANOVA and Student-Newman-Keuls post hoc test, 
n=4, * P<0.05). 
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Figure S8. TUBA4A staining of SALS cases and controls. Sections of spinal cord 
and motor cortex from 3 different SALS cases and controls were stained with an 
antibody to TUBA4A that specifically targets the C-terminal part of the protein, which 
differs from other members of the alpha-tubulin family. SALS cases were positive for 
TDP-43 aggregates and negative for known causative mutations. As shown, 
immunohistochemistry did not detect aggregates of TUBA4A or differences between 
case and control samples. Clear staining of the perikarya and neuropil region in both the 
spinal cord and motor cortex was observed. 
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Figure S9. Lack of co-localization of wild-type TUBA4A with TDP-43 aggregates. 
COS7 cells were co-transfected with constructs expressing wild-type HA-TUBA4A and a 
GFP-labeled C-terminal fragment of TDP-43, which produces cellular aggregates. At 
twenty-four hours post transfection, the cells were fixed and stained with anti-HA 
antibodies. Scale: 10 µm. 
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Figure S10. Quantitation of incorporation of TUBA4A in the microtubule network. 
Primary astroglial cells were transfected with the HA-TUBA4A constructs and fixed 4 
days after transfection. After staining, the cytoskeletal incorporation of HA-tagged 
TUBA4A was quantitated as described in the Methods section. Briefly, ImageJ was 
used to apply a circularity filter to a thresholded image to remove granular staining. The 
resulting image represented the filamentous HA staining. The ratio between the 
fluorescence intensities of the filtered cytoskeleton versus the thresholded image 
resulted in an incorporation index ranging from 0 (no incorporation) to 1 (complete 
microtubule incorporation). Examples of the quantitation of images are shown. 
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Figure S11. Mutant R320C TUBA4A alters microtubule dynamics. COS7 expressing 
wild-type and R320C TUBA4A were treated with nocodazole as described in Figure 3. 
The percentage of cells containing microtubules positive for both HA and TUBA4A 
protein is reduced in mutant TUBA4A-expressing cells compared to the wild-type 
control. Bars represent mean and SEM (Student’s t test; n=3, * p<0.05, ** p<0.01). 
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Figure S12. Altered microtubule acetylation in mutant TUBA4A expressing cells. 
Representative images of PMNs transfected with HA-tagged TUBA4A mutants (red) 
and immunostained with an antibody specific to acetylated tubulin (green). DAPI (blue) 
was used to identify the nucleus. Scale bars: 10 µm. 
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Figure S13. Relative expression of tubulin subunits in the primary motor cortex 
with age. RNA-Seq results derived from the primary motor cortex were downloaded 
from the BrainSpan Atlas of the Developing Human Brain (http://www.brainspan.org). 
Expression at each age was normalized to the expression at 12 pcw. For time points in 
which multiple samples were sequenced, the average was used. The relative 
expression (log2) was plotted for each age. As shown, TUBA4A expression increases 
over time whereas most other subunits responsible for developmental defects display 
their highest expression prenatally. 
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Figure S14. Relative expression of tubulin subunits during mouse brain 
development. Microarray expression data was downloaded from the NCBI’s Gene 
Expression Omnibus (GEO)(DataSet Record GDS4502) for the tubulin subunits shown. 
Changes in expression in mouse brains (n=6) between embryonic day 14 and 
postpartum day 14 are plotted. Hybridizations were performed on the Affymetrix Mouse 
Genome 430 2.0 Array. Error bars represent standard deviations. Similar to results in 
human primary motor cortex, TUBA4A expression increases over time whereas most 
other subunits responsible for developmental defects display their highest expression 
prenatally. 
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Figure S15. Relative expression of exogenous TUBA4A. HEK293 cells were 
transfected with HA-TUBA4A constructs and protein lysates collected 48 hours after 
transfection. The expression level of the HA-tagged proteins was compared to 
endogenous TUBA4A (top panel) or to overall α Tubulin expression (bottom panel) 
using specific antibodies (TUBA4A, Abgent; αTubulin, clone DM1A, Sigma Aldrich). All 
HA-TUBA4A proteins were expressed at similar levels, with an approximate 1:1 and 
0.2:1 ratio compared to endogenous TUBA4A and all α Tubulins, respectively. The 
epitopes recognized by both antibodies are deleted in the TUBA4AW407X mutant, which 
was thus not included in this analysis. 
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Figure S16. Stratification analysis of exome sequenced samples. Exome 
sequenced samples were subject to stratification analysis using the software application 
package PLINK. Pairwise genome-wide identity-by-state distances were calculated 
followed by linkage hierarchical cluster analysis and classical multidimensional scaling. 
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FALS Controls 
Ireland 16 6 
Italy 97 6 
Netherlands 8 0 
Spain 29 6 
United Kingdom 132 7 
United States 81 6 
Total 363 31 
 
 
Table S1. Summary of samples subject to exome sequencing in the discovery 
cohort. 
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Total Samples 403 
Cases 372 
Controls 31 
Total reads 41,430,525,586 
Average reads per sample 102,805,274 
Total aligned reads 38,907,252,470 
Average aligned reads per sample 96,544,051 
Average % reads aligned 95.04% 
Total aligned bases 3,229,103,417,870 
Average aligned bases per sample 8,012,663,568 
Total on target bases 1,301,439,397,693 
Average on target bases per sample 3,229,378,158 
Average mean target coverage per sample 90.44 
Average % target bases with 2x coverage per sample 97.04% 
Average % target bases with 10x coverage per sample 93.11% 
Average % target bases with 20x coverage per sample 88.06% 
Average % target bases with 30x coverage per sample 81.96% 
 
 
Table S2. Summary statistics for exome sequencing of the FALS discovery set. 
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Total Average Per Sample 
Coding SNPs 165,934 15935.69 
Non-synonymous SNPs 99,910 7575.88 
Synonymous SNPs 66,024 8359.81 
Rare Coding SNPs (MAF<0.005) 111,394 1442.66 
Rare Non-synonymous SNPs 70,878 790.64 
Rare Synonymous SNPs 40,516 652.02 
Novel Coding SNPs 41,431 118.87 
Novel Non-synonymous SNPs 28,011 79.88 
Novel Synonymous SNPs 13,420 38.98 
 
 
Table S3. Coding variants identified by exome sequencing. 
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PolyPhen-2 SIFT MutationTaster GERP PhyloP 
Rank Gene P Gene P Gene P Gene P Gene P 
1 TUBA4A 9.09E-06 SIDT2 3.84E-05 TUBA4A 4.87E-05 TUBA4A 4.87E-05 TUBA4A 4.87E-05 
2 STK24 1.76E-05 TUBA4A 4.87E-05 SLAMF7 5.24E-05 PKD1L1 1.38E-04 PKD1L1 4.90E-05 
3 LRRFIP1 2.61E-05 ALDH2 1.34E-04 ASNSD1 9.09E-05 ALDH2 2.20E-04 FARP1 1.69E-04 
4 NIN 6.07E-05 NIN 2.82E-04 LRRFIP1 1.92E-04 JAZF1 2.26E-04 KCTD20 1.94E-04 
5 MATR3 9.09E-05 PRICKLE1 3.15E-04 XYLT1 2.89E-04 FARP1 2.35E-04 ALDH2 2.20E-04 
6 NCOR1 1.86E-04 GTF3C1 3.15E-04 NCOR1 3.57E-04 NCOR1 2.44E-04 JAZF1 2.26E-04 
7 CLK1 2.26E-04 STK24 4.14E-04 MSLN 4.14E-04 KCTD20 2.74E-04 NCOR1 2.98E-04 
8 PKD1L1 3.94E-04 MAPK13 4.91E-04 ING5 4.14E-04 XYLT1 2.98E-04 XYLT1 2.98E-04 
9 OR10W1 4.14E-04 ATRN 4.91E-04 RASSF4 4.91E-04 GLYAT 3.14E-04 GLYAT 3.14E-04 
10 C15orf32 5.58E-04 INPP1 5.58E-04 PPM1G 4.91E-04 BTBD16 3.72E-04 ASNSD1 5.17E-04 
 
 
Table S4. Ranking and P values of top hits from the gene-based rare variant 
analysis. 
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Mutation Chr:Position 
Reference 
Allele 
Alternative 
Allele Codons Exon Country 
G43V 2:220116828 C A GGT-GtT 2 Italy 
T145P 2:220115988 T G ACT-cCT 4 US 
R215C 2:220115778 G A CGC-tGC 4 Spain 
R320C 2:220115463 G A CGT-tGT 4 Italy 
R320H 2:220115462 C T CGT-CaT 4 UK 
A383T 2:220115274 C T GCC-aCC 4 Italy 
K430N 2:220115131 C G AAG-AAc 4 Netherlands 
W407X 2:220115200 C T TGG-TGa 4 Italy 
 
 
Table S5. Description of mutations identified in TUBA4A. 
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Mutation PolyPhen-2 Score Prediction Frequency 
 
R215C 0.036 Benign 1/363 
 R320H 0.822 Possibly Damaging 1/363 
FALS R320C 0.917 Possibly Damaging 1/363 
 A383T 0.995 Probably Damaging 1/363 
 W407X N/A N/A 1/363 
    
Total: 5/363 
 
V68A 0.004 Benign 1/4300 
European EVS I276V 0 Benign 1/4300 
 V375M 0.231 Benign 1/4300 
    
Total: 3/4300 
 
 
Table S6. Description of non-synonymous variants identified in FALS and in EVS 
European Americans. 
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FALS 
Australia 63 
Canada 52 
Italy 4 
Netherlands 37 
Spain 10 
United States 106 
Total 272 
 
 
Table S7. Summary of samples screened for TUBA4A mutations in the replication 
cohort. 
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 FALS 
C9orf72 24 
SOD1 32 
TARDBP 13 
FUS 12 
PFN1 3 
UBQLN2 3 
VAPB 2 
Total 89 
 
 
Table S8. Summary of ALS samples with known mutations/expansions sequenced 
for TUBA4A mutations. 
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Mutation Gender 
ALS 
family 
history 
Other ND 
family 
history 
Age at 
onset 
(yrs.) 
Site of 
onset 
Disease 
Duration 
(mo.) 
Clinical 
Phenotype Dementia 
Atypical 
features 
G43V M SALS dementia 52 spinal 45 UMN/LMN yes (FTD) no 
T145P M FALS dementia 48 spinal 69 UMN/LMN no no 
R215C F FALS dementia 78 spinal n/a UMN/LMN yes (FTD) no 
R320C M FALS no 64 spinal 12 UMN/LMN no no 
R320H F FALS no 41 spinal 33 UMN/LMN no no 
A383T M FALS no 71 spinal 18 UMN/LMN no no 
K430N F FALS no 64 spinal 42 UMN/LMN no no 
W407X F FALS no 66 spinal 36 UMN/LMN no no 
 
 
Table S9. Clinical characteristics of ALS patients with TUBA4A mutations. Disease 
duration is calculated to the last follow-up. ND stands for other neurodegenerative 
disorders. 
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Mutation 
EVS-European 
Americans 
EVS-African 
Americans 
1000Genomes 
Project 
Internal 
Sequencing Total 
G43V 0/4300 0/2200 0/1053 1/5510 1/13,063 
T145P 0/4300 0/2200 0/1053 0/5510 0/13,063 
R215C 0/4300 0/2200 0/1053 0/5510 0/13,063 
R320C 0/4300 0/2200 0/1053 0/5510 0/13,063 
R320H 0/4300 0/2200 0/1053 0/5510 0/13,063 
A383T 0/4300 1/2200 0/1053 0/5510 1/13,063 
K430N 0/4300 0/2200 0/1053 0/5510 0/13,063 
W407X 0/4300 0/2200 0/1053 0/5510 0/13,063 
 
 
Table S10. Analysis of TUBA4A mutations in control populations. 
 
 
 
  
 27 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES  
 
Human subjects and Plasmids. 
DNA samples were collected from familial and sporadic ALS cases and control 
individuals after informed consent was obtained. All protocols were approved by the 
Institutional Review Boards at the institutions involved. A subset of the samples was 
obtained from the NINDS Repository at Coriell Cell Repositories. All FALS were 
screened for known causative mutations/repeat expansions in SOD1, C9orf72, 
TARDBP, FUS, PFN1, UBQLN2, OPTN, VCP and ANG and eliminated if a causative 
alteration was observed. Expression constructs were created by synthesizing the wild-
type and mutant coding region with an HA epitope tag at the N-terminus (DNA2.0) and 
subcloning into the vector pJ603. HA-tagged TUBA4A constructs were initially tested in 
HEK293 cells. Similar expression to the endogenous protein was achieved after 48 
hours in transiently transfected cells (Figure S15). The vector expressing the GFP-
labeled C-terminal fragment of TDP-43 (amino acids 208-414) was described previously 
(Fallini et al., 2012). 
 
Exome Sequencing and Rare Variant Analysis 
Exome sequencing reads were aligned to a human reference (hg19) using BWA 
(Burrows-Wheeler Aligner) and processed using the Genome Analysis ToolKit (GATK). 
After removal of duplicate reads, indel realignment (GATK IndelRealigner), and base 
quality recalibration (GATK TableRecalibration) was performed. Variant detection and 
genotyping were performed using the UnifiedGenotyper (UG) tool from GATK. Variants 
not passing quality control criteria were eliminated (QD<5.0, HRun>3, MQ<40.0, 
FS>60.0, HaplotypeScore>13.0, MQRankSum< -12.5, ReadPosRankSum< -8.0) and 
genotypes with low quality (GQ<50) were set to missing. Samples were also excluded if 
they demonstrated low call rate (<0.75), relatedness to another sample (portion of the 
genome IBD > 0.2 or clinically reported), excess homozygosity/heterozygosity or if the 
gender determined by genotypes did not match the clinically reported gender. 
Stratification analysis was additionally applied to all remaining samples based on the 
distribution of pairwise genome-wide identity-by-state distances followed by complete 
linkage hierarchical cluster analysis and classical multidimensional scaling (Figure S16). 
Outlying samples were eliminated resulting in the final set of FALS used for rare variant 
analysis.   
 
Rare variant analyses were performed by logistic regression of case-control status with 
respect to the aggregated count of minor alleles in a given gene window. Regression 
was performed using Firth's penalized likelihood method to avoid errors of model fitting 
in the event of data separation (where gene variants occur exclusively in the case or 
control cohort)(Heinze and Schemper, 2002). For controls, genotype summaries from 
4300 European Americans were downloaded from the NHLBI’s Exome Variant Server. 
These genotypes were randomly assigned to 4300 simulated individuals. Variants were 
filtered to those showing 90% call rate in either ESP data set or FALS. Gene selection 
was based on the initial set that passed quality control standards of the ESP study 
(14,931 autosomal genes). These genes were further restricted to those which 
displayed an 85% call rate over 85% of the coding region in the EVS resulting in the 
final set of 12,487 genes subject to rare variant analysis.  
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Variants were annotated as damaging by PolyPhen-2 (score> 0.446) or representing 
stop gain/loss variants. Additional filtering procedures included SIFT (“damaging”), 
Mutation Taster ("disease causing automatic" or “disease causing”), GERP (GERP++ 
score>0), and phyloP (score>0). Variants that did not display a 90% call rate in either 
cases or controls were eliminated from the analysis. Gene windows and predicted 
variant effects were defined based on protein coding RefSeq transcripts only. Variants 
were only included for analysis if the associated minor allele frequency did not exceed 
what would be expected of a typical ALS mutation on the basis of prior publications. 
Specifically, Mendelian ALS variants identified to date have generally been reported to 
account for <1% of population based patient cohorts (Chio et al., 2012; Kenna et al., 
2013). The lifetime risk of ALS is ~1/400 (Johnston et al., 2006), meaning that even in 
the event of penetrance as low as 50%, it would not be expected to observe a given 
ALS mutation in more than a single control (p<0.05). To allow for the potential of a 
single control occurrence and up to 3 case occurrences (~1% of patients), a maximum 
minor allele frequency of 0.0004 (4 occurrences) was imposed. Multiple testing 
correction was performed through permutation correction as recommended by (Kiezun 
et al., 2012). Briefly, the significance of each gene association in the observed dataset 
was calculated. Case-control labels were then randomly shuffled 10,000 times and the 
logistic regression analysis was repeated on each permuted dataset to generate a null 
p-value distribution. For each gene p-value from the observed dataset analysis, Pcorrected 
was calculated as the proportion of permuted datasets where an association of equal or 
greater significance was observed across any gene. This corresponds to a direct and 
empirical measure of family-wise error rate which is preferable to Bonferroni correction 
for reasons discussed in (Kiezun et al., 2012). The genomic inflation factor was 
calculated as previously described (Dadd et al., 2009). All data processing and rare 
variant analyses were performed using scripts prepared for bash version 4.2.24, python 
version 2.6.5 and R version 3.0.1. 
 
Motor neuron culture and transfection 
Primary motor neurons were isolated from E12.5 mouse embryos as previously 
described (Liu et al., 2012; Oprea et al., 2008). Briefly, spinal cords were dissociated in 
0.1% trypsin for 12 minutes at 37ºC, and motor neurons were isolated by density 
centrifugation on a 6% Optiprep (Sigma-Aldrich) cushion. Cells were plated on poly-
ornithine and laminin-coated glass coverslips in growth medium (Neurobasal, 2% horse 
serum, 2% B27, 10nM BDNF, CNTF, GDNF) and transfected at 2 days in vitro (DIV) 
with Neuromag (OZ Bioscience) as previously described (Fallini et al., 2010). Motor 
neurons were fixed 4 days post transfection (dpt) with 4% paraformaldehyde for 15 
minutes and processed for immunofluorescence. For the extraction of cytosoluble 
proteins, motor neurons were permeabilized at 7 dpt with 0.1% Triton-X100 in 
cytoskeletal stabilizing buffer (4M Glycerol, 25mM PIPES, 1mM EGTA, 1mM MgCl2) for 
5 minutes prior to fixation. After blocking in 5% bovine serum albumin (BSA) for 45 
minutes, cells were hybridized with the primary antibodies (mouse anti-HA 1:1000, 
MMS-101R-200, Covance; rabbit anti-HA 1:100, Sigma-Aldrich; mouse anti-ubiquitin 
1:100, Life Technologies; rabbit anti-β-tubulin 1:200, Cell Signaling Technology; mouse 
anti-acetylated tubulin 1:500, Sigma-Aldrich) diluted in 5% BSA for 1 hour at room 
temperature or overnight at 4ºC. AlexaFluor 488 and AlexaFluor 594-conjugated 
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secondary antibodies were diluted 1:500 in 5% BSA and hybridized for 1 hour at room 
temperature. Coverslips were mounted with Prolong Gold mounting medium Life 
Technologies) and imaged with a widefield fluorescence microscope equipped with a 
high resolution/sensitivity camera (Leica). Image stacks (10 stacks, 0.2µm thickness) 
were deconvolved (Autoquant, MediaCybernetics) and analyzed using ImageJ. 
 
Tubulin Dimerization Assay 
In vitro translation of HA-TUBA4A was performed using the TNT T7 Coupled 
Reticulocyte Lysate system (Promega). For non-denaturing gel electrophoresis, the 
products were diluted 1:1 in sample buffer (160 mM MES pH 6.86, 2mM MgCl2, 2 mM 
EGTA, 1 mM GTP, 20% Glycerol), immediately loaded onto a non denaturing gel (4.5% 
polyacrylamide in 80mM MES pH 6.86, 1mM MgCl2, 1mM EGTA, 1mM GTP) and run at 
95 volts for 1.5 hours. For SDS-gel electrophoresis, the reaction products were diluted 
in 2X Laemmli buffer, boiled for 5 minutes and loaded onto a 4-20% Mini-PROTEAN 
TGX gel (Bio-Rad). Proteins were transferred to a 0.45 µm nitrocellulose membrane for 
10 minutes at 1.2 amp/25 volts on the Trans-Blot Turbo Transfer System (Bio-Rad). HA-
TUBA4A was detected via chemiluminescence using mouse HA antibodies (MMS-
101R-200, Covance), goat anti-mouse HRP conjugate (sc-2005, Santa Cruz) and 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). 
 
HEK293 cell culture and immunofluorescence  
HEK293T cells were maintained in DMEM supplemented with 10% fetal bovine serum, 
100 units/ml penicillin and 100 µg/ml streptomycin at 5% CO2. All reagents were 
purchased from Sigma-Aldrich. Transient transfections were performed in 6-well or 12-
well plates using Lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s instructions. After 48-hour transfection, cells were processed for 
immunofluorescence analysis or protein solubility assay. For immunofluorescence, cells 
were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) at room 
temperature for 15 minutes, permeabilized with 0.2% Triton X-100 at room temperature 
for 5 minutes followed by blocking with 5% BSA in PBS at room temperature for 45 
minutes. Incubation with primary antibodies (anti-HA, 1:100, Sigma-Aldrich anti-
ubiquitin; 1:100, Life Technologies) was performed in blocking solution overnight at 4°C. 
The fluorescent-tagged secondary antibodies AlexaFluor 488 and AlexaFluor 594 
(1:500, Jackson Immunoresearch) was used for detection. As a negative control, the 
primary antibody was replaced by normal goat serum. Slides were mounted with 
ProLong Gold antifade reagent containing DAPI to visualize the nuclei. 
 
Quantification of Microtubule Incorporation 
Quantification of HA-TUBA4A incorporation into microtubules was performed using 
imageJ. For each image, a region of interest (ROI) was selected for each HA-TUBA4A 
positive cell and the signal was thresholded to remove background noise. A circularity 
filter (circularity index ≥ 0.2) was then applied to the thresholded ROI to remove 
granular staining. The resulting image represented the filamentous HA staining. The 
ratio between the fluorescence intensities of the filtered cytoskeleton versus the 
thresholded ROI yielded an incorporation index ranging from 0 (no incorporation) to 1 
(complete microtubule incorporation). The frequency distribution of these values was 
compared using the Kolmogorov-Smirnov test. 
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Microtubule Repolymerization Assay 
COS7 cells were cultured in DMEM supplemented with 10% FBS (Life Technologies) 
and transfected with Lipofectamine 2000 (Life Technologies) accordingly to the 
manufacturer’s recommendations. Thirty-six hours after transfection, cells were treated 
with 10µM nocodazole (Sigma-Aldrich) for 2 hours and allowed to recover in 
nocodazole-free medium for 0, 2.5, 5, 10, and 15 minutes before fixation with cold 
methanol. 
 
Protein Fractionation and Insolubility assay 
Protein fractionation was performed as previously reported with minor 
modifications(Koyama et al., 2006). Transfected HEK293T cells were collected in 300µl 
PBS buffer with protease inhibitors (Sigma-Aldrich) for each well of a 6-well culture 
plate. Samples were sonicated and centrifuged at 13,500xg for 10 minutes at 4°C. The 
supernatant was collected as the PBS-soluble fraction. The remaining pellet was 
sequentially resuspended in 150µl 1% Triton X-100, 5% SDS, and 8M urea, sonicated 
and centrifuged at 13,500xg for 10 minutes. All centrifugation steps were performed at 
4°C, except for those with SDS, which were performed at room temperature to prevent 
precipitation. For the insolubility assay, transfected HEK293 cells were harvested with 
cold PBS with protease inhibitors, pelleted, resuspended in NP-40 lysis buffer (20mM 
Tris-HCl, pH 7.4, 1% NP-40, 150mM NaCl, 10% glycerol, 1mM DTT) containing 
proteasome inhibitors followed by sonication. Samples were incubated at 4oC for 30 
minutes, centrifuged, and the pellets washed with NP-40 lysis buffer and resuspended 
in urea-SDS buffer (NP-40 lysis buffer containing 8M urea, 3% SDS) followed by 
sonication. Proein fractions from both assays were run on a 10% polyacrylamide gel 
with equivalent volumes loaded per sample. Antibodies used: mouse HA (Cell Signaling 
Cat. No 2367) and IRDye 680 anti-mouse secondary antibody for detection (Li-Cor); 
rabbit GAPDH and rabbit Lamin (used as controls) and 800 anti-rabbit secondary 
antibody (Li-Cor). 
 
Immunohistochemistry 
Tissue from ALS cases and healthy controls was available from the MRC London 
Neurodegenerative Diseases Brain Bank. In brief, sections of 7µm thickness were cut 
from paraffin-embedded tissue blocks, then deparaffinised in xylene. Endogenous 
peroxidases were blocked by immersion in 2.5% H2O2 in methanol and 
immunohistochemistry performed. To enhance antigen retrieval sections were kept in 
citrate buffer (pH 6) for 10 minutes following microwave treatment. After blocking in 
normal swine serum (1:10, DAKO) in Tris-buffered saline (pH 7.6), anti-TUBA4A 
antibody (1:100, Cat.# AP13535b, Abgent) was applied overnight at 4°C.  Following 
washes, sections were incubated with biotinylated secondary antibody (swine anti-
rabbit, 1:100, DAKO, UK), followed by avidin:biotinylated enzyme complex (Vectastain 
Elite ABC kit, Vector Laboratories). Finally sections were incubated for 10-15 min with 
0.5 mg/mL 3,3′-diaminobenzidine chromogen (Sigma-Aldrich) in TBS containing 0.05% 
H2O2. Sections were counterstained with Harris’ haematoxylin and immuno-staining was 
analysed using a light microscope (Leica).  
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